TollB-001 tablets for moderate to severe rheumatoid arthritis
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This trial tests an experimental tablet, TollB-001, for people with moderate to severe rheumatoid arthritis who have not responded well to standard treatments. The goal is to see if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have a confirmed diagnosis of rheumatoid arthritis (RA) with ongoing moderate to severe disease activity.
- You have tried at least one standard RA medication (like methotrexate or leflunomide) and it did not work well enough or caused side effects.
- You have not used certain advanced RA treatments such as JAK inhibitors (e.g., tofacitinib) or biologic drugs before.
- You are willing to avoid pregnancy during the study and for 3 months after the last dose.
- You do not have active infections, certain cancers, or other serious health conditions that could affect the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called TLL-018 for people with moderate to severe rheumatoid arthritis who have not improved enough with standard disease-modifying drugs. It aims to see if the drug can reduce joint pain and swelling.
This trial tests a new drug called telitacicept for people with rheumatoid arthritis (RA) that hasn't improved after trying multiple treatments. It aims to see if the drug can reduce joint pain and swelling when other medications have failed.
This trial tests a new medicine called VDJ001 for people with moderate to severe rheumatoid arthritis who are already taking methotrexate. The goal is to see if VDJ001 helps reduce joint pain and swelling better than a placebo.
This trial tests an investigational drug called JAB-8263 for people with active rheumatoid arthritis. It aims to see if the drug can help reduce inflammation and improve symptoms.
This trial tests an investigational drug for people with moderate-to-severe rheumatoid arthritis who haven't responded well to previous treatments. It aims to see if the drug can reduce joint pain and swelling.
This early-stage study tests a new injectable medicine (KT501) for people with moderate to severe rheumatoid arthritis who have not responded well enough to other treatments and have specific antibodies in their blood. It aims to see how safe and well-tolerated the drug is.
Hear when a new Rheumatoid Arthritis (RA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.